Welcome to our dedicated page for Lemaitre Vasculr news (Ticker: LMAT), a resource for investors and traders seeking the latest updates and insights on Lemaitre Vasculr stock.
LeMaitre Vascular (NASDAQ: LMAT) delivers innovative medical devices for vascular surgeons worldwide. This page provides centralized access to official announcements, financial disclosures, and strategic developments from the leader in peripheral vascular disease solutions.
Investors and medical professionals will find timely updates on product launches, regulatory milestones, and financial results. Track advancements in carotid shunts, vascular grafts, and other devices critical to open vascular surgery.
Our curated news collection enables you to monitor LMAT's progress in addressing circulatory challenges through cutting-edge technologies. Discover updates on manufacturing expansions, clinical study outcomes, and partnerships shaping the future of vascular care.
Bookmark this page for direct access to verified information about LeMaitre Vascular's surgical innovations and market leadership. Check regularly for new developments impacting the medical device sector and patient care standards.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its Q2 2022 financial results on July 28, 2022, after market close. The company has scheduled a conference call at 5:00 PM ET the same day to discuss the results, business highlights, and future outlook. LeMaitre specializes in developing and marketing devices and services for treating peripheral vascular disease, which impacts over 200 million people globally.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that its President, David Roberts, will present at the Sidoti Summer Small Cap Virtual Conference on June 15, 2022, at 2:30 PM ET. The company specializes in devices and services for treating peripheral vascular disease, which affects over 200 million individuals globally. LeMaitre develops and markets both disposable and implantable vascular devices tailored for vascular surgeons. For additional information, visit www.lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) will participate in two investor conferences in May and June 2022. CFO JJ Pellegrino is set to present at the UBS Global Healthcare Conference on May 23 at 2:00 PM ET in New York City. Additionally, President David Roberts will present at the Jefferies Healthcare Conference on June 8 at 9:30 AM ET, also in New York City. LeMaitre is a key provider of devices and services for treating peripheral vascular disease, affecting over 200 million people globally.
LeMaitre (NASDAQ: LMAT) reported its Q1 2022 results, highlighting a sales increase of $39.6 million, up 10% year-over-year. Operating income remained flat at $7.9 million with a 20% operating margin. The company announced a quarterly dividend of $0.125 per share and provided updated guidance for 2022, forecasting sales of $160-$164 million. Key developments included a buyout of its Korean distributor and the closure of its St. Etienne factory, expected to reduce future operating costs. However, the strong U.S. dollar negatively impacted both sales and operating income guidance.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced it will release its Q1 2022 financial results on April 28, 2022, post-market. A conference call is scheduled for 5:00 PM ET to discuss the results and company outlook. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million globally. The company develops and markets both disposable and implantable vascular devices targeted at vascular surgeons. Further details can be found at www.lemaitre.com.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced that Chief Financial Officer JJ Pellegrino will present at the 21st Annual Needham Virtual Healthcare Conference on April 14, 2022, at 10:15 AM ET. LeMaitre specializes in devices and services for treating peripheral vascular disease, impacting over 200 million globally. The company focuses on developing disposable and implantable vascular devices tailored for vascular surgeons.
LeMaitre (Nasdaq:LMAT) has been added to the NASDAQ US Broad Dividend Achievers Index, recognizing companies with a decade of increasing dividends. Since initiating dividends in 2011, LeMaitre's payout per share rose from $0.08 to $0.44 in 2021, achieving an 18.6% compounded annual growth rate. A new quarterly dividend of $0.125 will be distributed on March 24, 2022. CEO George W. LeMaitre emphasized the company's commitment to profitability and an improved balance sheet through consistent dividend increases.
LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced its participation in four significant investor conferences this March. The 34th Annual Roth Conference is scheduled for March 14, 2022, with President David Roberts presenting. Following that, the Oppenheimer 32nd Annual Healthcare Conference takes place on March 16, 2022, featuring CFO JJ Pellegrino. On March 17, 2022, Roberts will present at the Barclays Global Healthcare Conference, and the month concludes with the KeyBanc Life Sciences & MedTech Investor Forum on March 22, 2022.
LeMaitre (Nasdaq:LMAT) reported Q4 2021 sales of $39.5 million, a 5% increase year-over-year, driven by higher sales of bovine grafts and patches. Operating income fell 13% to $8.3 million, with an operational margin of 21%. The company announced a 14% increase in its quarterly dividend to $0.125 per share, marking the 11th consecutive year of dividend growth. For Q1 2022, guidance suggests sales between $37.7 million and $39.7 million, with a gross margin of 66.2%. Full-year 2022 guidance anticipates sales of $162 million to $166 million, aiming for an EPS of $1.35 to $1.45.
LeMaitre Vascular, Inc. (LMAT) will release its fourth quarter 2021 financial results on February 24, 2022, after market close. A conference call is scheduled for 5:00 PM ET that day to discuss the results and company outlook. The company provides devices and services for peripheral vascular disease, affecting over 200 million people globally. Investors can access the live call by dialing 800-773-2954 or through a webcast on the company's investor relations website.